CHERRY BEKAERT LLP – Trademark Portfolio
Entity Type: 20
CHERRY BEKAERT LLP holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 35 (Advertising & Business) — 6 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include CHERRY BEKAERT LLP, YOUR GUIDE FORWARD, CHERRY, BEKAERT & HOLLAND, and CB CHERRY BEKAERT LLP YOUR GUIDE FORWARD. The owner is based in RICHMOND, VA.
200 SOUTH 10TH STREET
SUITE 900
RICHMOND, VA 23219
Showing of trademarks Trademarks
Trademark Classifications
CHERRY BEKAERT LLP's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Advertising; business management; business administration; office functions
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does CHERRY BEKAERT LLP have?
CHERRY BEKAERT LLP has 7 U.S. trademarks filed with the USPTO. Of these, 4 registered, 3 cancelled.
What trademark classes does CHERRY BEKAERT LLP file in?
CHERRY BEKAERT LLP files trademarks across 2 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 42 (Computer & Scientific). Class 35 covers advertising; business management; business administration; office functions.
What are CHERRY BEKAERT LLP's most well-known trademarks?
CHERRY BEKAERT LLP's registered trademark portfolio includes well-known marks such as CHERRY BEKAERT LLP, YOUR GUIDE FORWARD, CHERRY, BEKAERT & HOLLAND, and CB CHERRY BEKAERT LLP YOUR GUIDE FORWARD. These are among 4 currently registered trademarks in the portfolio.
What is CHERRY BEKAERT LLP's trademark registration success rate?
CHERRY BEKAERT LLP has a 57% trademark registration rate, with 4 out of 7 resolved applications resulting in successful registration. Currently, 0 applications are pending review.